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Purpose: The primary objective of the present study was to show the long lasting cardioprotective activity, at
different time-points, up to 18 month-follow-up, of telmisartan in preserving the systolic function (assessed as Strain
Rate-SR) in cancer patients treated with EPI both in the adjuvant and metastatic setting; the secondary objective
was to confirm the correlation of the cardioprotective activity of telmisartan with a reduction of inflammation and
oxidative stress induced by EPI.
Methods: Phase II single blind placebo-controlled randomized trial. Sample size 50 patients per arm: based on a
pre-planned interim analysis for early stopping rules, the study was discontinued for ethical reasons at 49 patients.
Cardiovascular disease-free patients with cancer at different sites eligible for EPI-based treatment randomized to:
telmisartan n = 25 or placebo n = 24. Echocardiography Tissue Doppler imaging (TDI) strain and strain rate was
performed, serum levels of proinflammatory cytokines (IL-6, TNF-α) and oxidative stress (reactive oxygen species,
ROS) were assessed at baseline, every 100 mg/m2 EPI dose and at 6-, 12- and 18-month follow-up (FU).
Results: Significant SR peak reduction in both arms was observed at t2 (cumulative dose EPI 200 mg/m
2) vs t0.
Conversely, at t3, t4, 6-, 12- and 18-month FU SR increased towards normal range in the telmisartan arm, while in
the placebo arm SR remained significantly lower. Differences between SR changes in the placebo and telmisartan
arm were significant from t3 up to 18 month-FU. IL-6 and ROS increased significantly in the placebo arm at t2 but
did not change in the telmisartan arm. A significant (p < 0.05) correlation between changes of SR vs IL-6 and ROS
was observed.
Conclusions: Our results suggest that the protective effect of telmisartan is long lasting, probably by ensuring a
permanent (at least up to 18-month FU) defense against chronic or late-onset types of anthracycline-induced
cardiotoxicity.
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Anthracyclines (ANT) are among the most effective
drugs against cancer and are used in a wide spectrum of
malignancies. Regrettably, their clinical use is limited by
the occurrence of dose-related cardiotoxicity (Paulides
and Wojnowski 2007).
Several studies have shown that anthracycline-induced
cardiotoxicity (CTX) is at least partially mediated by
chronic inflammation and oxidative stress: indeed,
proinflammatory cytokines interleukin-6 (IL-6), tumor ne-
crosis factor-alpha (TNF-α) and Reactive Oxygen Species
(Thompson, et al.) all play a central role (Meldrum, et al.
1998, Kupatt, et al. 1999). It has also been shown that the
use of a conventional cardioprotective agent, such as
dexrazoxane, together with chemotherapy, reduces the
expression of the NRF-2 gene (responsible for oxidative
stress response), which is over-expressed in patients
receiving ANT alone (Thompson, et al. 2010).
A recent and growing mass of evidence shows the in-
volvement of the renin-angiotensin-system (RAS) in the
ANT-induced CTX. The angiotensin II plays a crucial
role not only as a vasoconstrictor agent but also as a
mitogenic factor by interacting with angiotensin II type-
1 receptors (AT1Rs) in the cardiovascular myocytes
(Toko, et al. 2002). Cardiac dysfunction after doxorubi-
cin was not shown in the knockout rat for the AT1R
gene, a finding confirmed by the absence of apoptosis
and myofibrillar damage (Soga, et al. 2006). In a recent
study, the cardioprotective effect of angiotensin receptor
blocker (AT1Rs) telmisartan has been shown in rats ex-
posed to ANT (Iqbal, et al. 2008). The authors argued
that the effect was sustained by a decrease of oxidative
stress, which in turn is able to reduce the structural
damage of cardiomyocytes. As regards the possible role
of ARBs in mitogenesis and angiogenesis, it was ob-
served that these drugs were able to suppress the signal
transduction mediated by growth factors, such as the
epidermal growth factor (EGF), through the AT1R
antagonism (Ishiguro, et al. 2007). Furthermore, the ARB
telmisartan was shown to be able to inhibit the prolifera-
tion of prostate cancer cells through the activation of the
peroxisome proliferator-activated receptor-γ (PPAR-γ)
(Funao et al. 2008).
We previously identified an EPI-induced early myocar-
dial dysfunction, detected after low dose (200 mg/m2) of
EPI (Mercuro, et al. 2007). This dysfunction was shown
to be correlated to a significant increase of several bio-
logical markers of inflammation and oxidative stress and
persisted throughout the treatment with EPI and up to
18 month follow-up (Mantovani, et al. 2008).
In a previous phase II placebo-controlled study we
used telmisartan in order to prevent EPI-induced myo-
cardial damage (Cadeddu, et al. 2010). We aimed to ex-
ploit the ability of this drug to inhibit the productionof superoxide radicals by mitochondrial NADPH-
dependent oxidase and xanthine oxidase (Wenzel, et al.
2008) and to, at least partially, antagonize the PPAR-γ
activation (Stephen, et al. 2004). Our study showed that
telmisartan was able to reduce EPI-induced oxidative
stress/chronic inflammation and to reverse early myo-
cardial impairment (Cadeddu, et al. 2010).
The primary objective of the present study was to
show the long lasting cardioprotective activity, at
different time-points, up to 18 month-follow-up, of
telmisartan in preserving the systolic function (assessed
as Strain Rate-SR) in cancer patients treated with EPI
both in the adjuvant and metastatic setting; the second-
ary objective was to confirm the correlation of the
cardioprotective activity of telmisartan with a reduction
of inflammation and oxidative stress induced by EPI.
Patients and methods
Patient population and study protocol
From September 2008 to October 2009, 49 consecutive
eligible patients (male/female ratio: 12/37) with histolog-
ically confirmed tumors at different sites, previously un-
treated were enrolled. All eligible patients were included
in the study. The majority of patients (40 patients) had
early stage cancer and therefore were treated in the ad-
juvant setting while the remaining patients (9 patients)
had locally advanced or metastatic disease and were
treated in the metastatic setting. Patients eligible for
EPI-based chemotherapy regimen were randomized and
treated with a combination chemotherapy schedule
containing EPI. The great majority of patients followed a
schedule of 100 ± 30 mg/m2 every three weeks, while the
remaining patients followed a schedule other than 100 ±
30 mg/m2 every three weeks (for example 30 mg/m2
weekly). Patients were treated up to a maximal cumula-
tive dose of EPI 400 ± 30 (SD) mg/m2, according to the
international standardized protocols for EPI-based
administration.
Inclusion criteria were the following: patients aged
18–70 yo; blood pressure within the normal range (80/
120); echocardiographic LVEF value ≥55%; SR value in
the normal range (range: 1.7-2.1 cm/sec); Eastern Co-
operative Oncology Group (ECOG) performance status
score of 0–2 (Oken, et al. 1982); normal hepatic and
renal function (bilirubin ≤ 1.5 mg/dl, creatinine ≤
2.0 mg/dl); no concomitant medications known to inter-
fere with inflammatory and oxidative stress parameters
such as NSAIDs, aspirin, Cox-2 inhibitors.
Patients were not eligible if they had a history of
cardiac disease, hypertension, diabetes and/or had been
previously treated with mediastinal radiation therapy.
The study was one-Institution “independent”, single
blind randomized, placebo-controlled trial; it was ap-
proved by the Institutional Ethics Committee (“Azienda
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informed consent was obtained by all patients included
in the study. The trial was carried out in accordance
with Good Clinical Practices and the Helsinki
Declaration.
A blind randomization was performed: 25 patients were
randomized by a block randomization technique to the
telmisartan arm and 24 to the placebo arm. The random
allocation was generated by a data manager, patients were
enrolled by a physician (oncologist) and were then
assigned to intervention by another physician (oncologist).
None of the above mentioned people were involved in the
data evaluation.
Patients were treated with telmisartan (Micardis,
Boehringer-Ingelheim, Milan, Italy) 40 mg, 1 tablet/day, or
placebo starting one week before the beginning of EPI
treatment and up to six months after EPI discontinuation.
The telmisartan dose was chosen according to the safety
and efficacy shown in our previously published study
(Cadeddu, et al. 2010). The placebo tablets were supplied
from the Institutional Pharmacy and were identical
looking and tasting to telmisartan.Clinical and laboratory assessments
At enrollment, before randomization, as well as after each
subsequent administration of EPI, patients underwent
physical examination, blood pressure measurement, 12-
lead electrocardiogram and echocardiographic analysis
(conventional and Tissue Doppler Imaging, TDI, tech-
nique). The following laboratory tests were carried out:
blood and platelet count, BUN, uric acid, creatinine, blood
and urine electrolytes, direct and indirect bilirubin, AST,
ALT, γGT, alkaline phosphatase, iron, ferritinemia and
blood transferrin. Blood samples were collected for the
assessment of circulating levels of proinflammatory cyto-
kines (IL-6 and TNF-α), ROS and antioxidant enzymes
glutathione peroxidase (GPx) and superoxide dismutase
(SOD) from all patients. The instrumental and laboratory
variables were assessed at baseline (t0), 7 days after
reaching the EPI dose of 100, 200, 300, 400 mg/m2 (t1, t2,
t3 and t4, respectively) and at 6, 12 and 18 month-follow
up. The reported doses of EPI are to be always intended
as cumulative.Conventional echocardiography and TDI
Echocardiographic images were recorded using a com-
mercially available system equipped with TDI, Strain (S)
and Strain Rate (Khasraw et al. 2012) imaging (Toshiba
APLIO CV ultrasound system-SSA 770A/CV; Toshiba
Corp., Tochigi, Japan). LVEF was obtained from the ap-
ical 4-and 2-chamber views according to Simpson’s rule
and was considered abnormal under 55%.Conventional echocardiography parameters such as
left ventricular end diastolic diameter (LVEDD) and
atrial dimensions were assessed in both arms.
We performed a pulsed wave Doppler (PWD) examin-
ation of the LV inflow from the 4-chamber view with
the sample volume placed between the mitral leaflet tips
and the early (E) and late (A) diastolic peak velocities; E
deceleration time (DecT) was measured and then the E/
A ratio was derived. We evaluated the longitudinal func-
tion using pulsed TDI at the mitral annulus, placing the
sample volume in the basal segment of the
interventricular septum (IVS) from the apical 4-chamber
view: peak velocities in systole (Jones et al. 2009),
isovolumic relaxation time (IVRT), early (Em) and late
(Am) diastole were measured. LV longitudinal function
was evaluated from raw data; myocardial S and SR were
also quantified in the IVS. The same experienced echo-
cardiographer carried out all examinations of each indi-
vidual patient. To reduce inter-observer variability, all
echocardiographic data were randomly read by a second
experienced observer and an average value for each
measurement was calculated. Reproducibility of TDI
parameters in our laboratory had been previously docu-
mented (Cadeddu, et al. 2010).
Inflammatory and oxidative stress markers
In all patients, a blood sample was obtained by
venipuncture of antecubital vein at 8 a.m., after overnight
fasting. Levels of IL-6 and TNF-α were determined by
enzyme-linked immunosorbent assay (Immunotech,
Marseille, France) and expressed in pg/ml. ROS blood
levels were determined on fresh heparinized blood
samples using the free oxygen radicals test (FORT).
Results are expressed as FORT units (U), where 1 FORT
U corresponds to 0.26 mg/l of H2O2. The erythrocyte
antioxidant enzymes GPx and SOD were measured by
photometer using a commercially available kit (Ransod,
Randox Lab, Crumlin, United Kingdom) and expressed as
U/l and U/ml, respectively.
Timing of echocardiographic and biomarker assessments
Echocardiographic and biomarker assessments were car-
ried out according to the schedule reported in Table 1.
Statistical analysis
Considering an α type error of 0.05, a β type error of
0.10 and a difference of SR changes between arms of
10% of the primary endpoint (SR change) as clinically
meaningful, 50 patients should have been enrolled in
each arm.
An interim analysis on the basis of the early-stopping
rules was pre-planned. The futility stopping rule was de-
fined for a two-sided p value testing the superiority of
telmisartan in terms of SR change. A p value < 0.05
Table 1 Timing of echocardiographic and biomarker assessments
t0 t1 t2 t3 t4
Before EPI week 1 week 4 week 7 week 10
For EPI dose other than 100 ± 30 mg/m2 every three weeks
t0 t1 t2 t3 t4
Before EPI 1 week after reaching 100 ±
30 mg/m2
1 week after reaching 200 ±
30 mg/m2
1 week after reaching 300 ±
30 mg/m2
1 week after reaching 400 ±
30 mg/m2
For EPI dose 100 ± 30 mg/m2 every three weeks.
Table 2 Patient clinical characteristics
TEL PLA
Patients evaluated 25 24
Male/female 6/19 6/18
Age, years: mean ± SD (range) 59 ± 14 (27–78) 52.9 ± 9 53 ± 10
Alive 23 21
Dead 2 3
Tumor type TEL PLA
Breast 8 10
Endometrium 12 9
Non-Hodgkin’s lymphoma 1 2
NSCLC 0 1
Ovary 4 1










Abbreviations. ECOG PS: Eastern Cooperative Oncology Group performance
status; NSCLC: non-small cell lung cancer.
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favor placebo. The p value for stopping the study for ef-
ficacy was 0.01. At the time of stopping the study we
had reached a p value < 0.05.
Treatment arms were compared by the Student’s t-test
for changes. Differences between values measured at dif-
ferent times (different EPI doses) and at 6-, 12-and 18-
month FU were calculated by the ANOVA test, with
Bonferroni correction.
The correlation between instrumental (TDI) and la-
boratory variables was assessed by Pearson’s t-test (or
Spearman’s t-test for non-parametric variables).
Significant relationships were then examined by multi-
variate linear regression analysis.
Results were considered significant for p values ≤0.05.
Data are reported as mean ± SD. Statistical analysis was
performed using SPSS version 14 for Windows.
Results
Clinical characteristics of patients in each arm were well
balanced and are summarized in Table 2. All patients
reached the scheduled cumulative EPI dose of 400 mg/
m2. As regards tumor history, it should be noted that
overall 5 patients died at 5 ± 2 months after the end of
EPI treatment due to disease progression (PD): 2 pa-
tients in the telmisartan arm, 3 patients in the placebo
arm. The Consort Diagram is reported in Figure 1.
Moreover, at 18 month-FU PD occurred in 1/23 patients
in the telmisartan arm and in 2/21 patients in the pla-
cebo arm.
Serial assessment of 12-lead electrocardiograms over
time
At ECG monitoring, a normal morphology was observed
throughout the treatment in 33 patients; in 16 patients
(9 in the telmisartan and 7 in the placebo arm) we
observed widespread and unspecified changes during the
ventricular repolarization phase concurrent with t2 with
no significant differences between the telmisartan and
placebo arm.
Conventional echocardiography and TDI
In the placebo arm, at t3 and t4 we observed a significant
LV diastolic impairment, represented by a reduction inthe E/A ratio at PWD (p < 0.05). In the telmisartan arm
we observed a slight reduction in the E/A ratio, which,
however, did not reach statistical significance. No signifi-
cant abnormalities of LVEF and DecT were found in any
of the two arms throughout the treatment (Table 3).
Conventional echocardiography parameters, i.e. left
ventricular end diastolic diameter (LVEDD) and atrial di-
mensions were in the normal range and not different be-
tween arms at baseline and did not change during
treatment up to 18 month-FU (data not shown).
TDI echocardiographic analysis showed in the placebo
arm a LV diastolic impairment, highlighted by a reduction
in the Em/Am ratio measured in the basal portion of IVS,
first recognized at t2 (p‹0.05; Table 4): this worsened func-
tion persisted throughout the treatment, at t3 (p‹0.05) and
Figure 1 Consort Diagram.
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diastolic impairment did not occur. At 12 and 18 month-
FU Em/Am ratio returned within the t0 range in the
placebo arm. The other TDI parameters (Em, Sm, S) did
not show any significant changes during treatment up to
18 month-FU in any of the two arms (Table 4).
A significant reduction of the SR peak both in the
telmisartan and placebo arm was observed at t2 (cumula-
tive dose of 200 mg/m2 of EPI) in comparison to t0
(1.45 ± 0.33 s-1 vs 1.54 ± 0.35 s-1; NS). Conversely, at t3
(300 mg/m2 EPI), t4 (400 mg/m
2 EPI) and onwards the
SR increased reaching the normal range only in the
telmisartan arm, whilst in the placebo arm the SR
remained significantly lower as compared to t0 (base-
line). The differences between SR changes in the placebo
and telmisartan arm were significant at t3, t4 and at 6,12
and 18 month-FU (Figure 2).
Inflammation and oxidative stress markers
Serum levels of IL-6 increased significantly in the
placebo arm at t2, t3 and t4, in comparison to baselineTable 3 Conventional ecocardiographic parameters of systoli
Conventional echo t0 (n = 49) t2 (n = 49) t3 (n = 49)
LVEF
PLA 66 ± 5% 68 ± 6% 66 ± 5%
TEL 66 ± 7% 67 ± 6% 68 ± 4%
DecT
PLA 0.22 ± 0.04 0.24 ± 0.05 0.22 ± 0.02
TEL 0.19 ± 0.04 0.21 ± 0.04 0.20 ± 0.02
E/A
PLA 1.13 ± 0.14 1.08 ± 0.12 0.92 ± 0.05*
TEL 0.96 ± 0.12 0.86 ± 0.08 0.83 ± 0.07
LVEF, left ventricle ejection fraction; DecT, deceleration time; E/A, early and late dias
400 mg/m2 EPI; * p < 0.05 vs t0.(p < 0.05), but remained unchanged in the telmisartan
arm (p = 0.356). Thus, a significant difference was ob-
served from t2 to t4 between the two arms. No difference
was found between the two arms from 3 month-FU
onward (Figure 3).
Blood levels of ROS increased significantly in the
placebo arm at t2 and t3 in comparison to baseline (p =
0.016), whilst remained unchanged in the telmisartan arm
(p = 0.319) Thus, a significant difference was observed at
t2 and t3 between the two arms (Figure 4).
The remaining laboratory parameters (TNFα, GPx and
SOD) did not show significant changes in either of the
two arms throughout the study (Table 5).Correlations between echocardiography and biomarkers
Both in the placebo and in the telmisartan arm we corre-
lated the changes of ΔSR (calculated as Δ by subtracting
the values at t2 from values at baseline) to changes in
plasma levels of inflammation and oxidative stress
markers. We found a significant correlation between ΔSR,c and diastolic function in both arms
t4 (n = 49) 12-Month FU (n = 44) 18-Month FU (n = 44)
66 ± 5% 67 ± 5% 65 ± 7%
70 ± 6% 68 ± 4% 66 ± 6%
0.23 ± 0.04 0.22 ± 0.03 0.23 ± 0.04
0.21 ± 0.03 0.21 ± 0.04 0.20 ± 0.05
0.90 ± 0.06* 1.06 ± 0.42 1.06 ± 0.29
0.95 ± 0.14 0.87 ± 0.31 0.89 ± 0.24
tolic peak velocity ratio; t0, baseline; t2, 200 mg/m2 EPI; t3, 300 mg/m2 EPI; t4,
Table 4 TDI ecocardiographic parameters of systolic and diastolic function in both arms
TDI echo t0 (n = 49) t2 (n = 49) t3 (n = 49) t4 (n = 49) 12-Month FU (n = 44) 18-Month FU (n = 44)
Em
PLA 8.66 ± 4.90 8.64 ± 6.07 7.73 ± 4.90 7.54 ± 3.50 7.88 ± 2.07 7.65 ± 1.66
TEL 7.89 ± 2.14 7.33 ± 2.45 7.53 ± 2.17 6.93 ± 1.46 7.74 ± 1.58 7.49 ± 1.23
Em/Am
PLA 1.13 ± 0.26 0.85 ± 0.35* 0.72 ± 0.30* 0.75 ± 0.32* 0.96 ± 0.27 0.87 ± 0.33
TEL 0.90 ± 0.11 0.84 ± 0.07 0.85 ± 0.05 0.71 ± 0.23 0.78 ± 0.28 0.75 ± 0.27
Sm
PLA 7.15 ± 0.65 7.28 ± 1.71 7.28 ± 0.82 6.83 ± 0.69 7.25 ± 1.37 6.82 ± 0.87
TEL 7.33 ± 1.76 7.09 ± 1.21 7.04 ± 1.12 7.29 ± 1.08 7.33 ± 1.22 6.61 ± 0.93
Strain (S)
PLA 20.89 ± 1.96 20.75 ± 2.06 18.00 ± 2.55 18.65 ± 1.25 16.78 ± 2.22 17.78 ± 2.73
TEL 22.80 ± 1.54 21.20 ± 1.86 20.40 ± 0.94 19.90 ± 0.92 19.64 ± 1.82 19.18 ± 1.70
TDI echo t0 (n = 49) t2 (n = 49) t3 (n = 49) t4 (n = 49) 12-Month FU (n = 44) 18-Month FU (n = 44)
Em
PLA 8.66 ± 4.90 8.64 ± 6.07 7.73 ± 4.90 7.54 ± 3.50 7.88 ± 2.07 7.65 ± 1.66
TEL 7.89 ± 2.14 7.33 ± 2.45 7.53 ± 2.17 6.93 ± 1.46 7.74 ± 1.58 7.49 ± 1.23
Em/Am
PLA 1.13 ± 0.26 0.85 ± 0.35* 0.72 ± 0.30* 0.75 ± 0.32* 0.96 ± 0.27 0.87 ± 0.33
TEL 0.90 ± 0.11 0.84 ± 0.07 0.85 ± 0.05 0.71 ± 0.23 0.78 ± 0.28 0.75 ± 0.27
Sm
PLA 7.15 ± 0.65 7.28 ± 1.71 7.28 ± 0.82 6.83 ± 0.69 7.25 ± 1.37 6.82 ± 0.87
TEL 7.33 ± 1.76 7.09 ± 1.21 7.04 ± 1.12 7.29 ± 1.08 7.33 ± 1.22 6.61 ± 0.93
Strain (S)
PLA 20.89 ± 1.96 20.75 ± 2.06 18.00 ± 2.55 18.65 ± 1.25 16.78 ± 2.22 17.78 ± 2.73
TEL 22.80 ± 1.54 21.20 ± 1.86 20.40 ± 0.94 19.90 ± 0.92 19.64 ± 1.82 19.18 ± 1.70
Em,TD early diastolic peak velocity; Em/Am,TD early and late diastolic peak velocity ratio; Sm,TD systolic peak velocity; * p < 0.05 vs t0.
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p = 0.032) only in placebo arm.Safety
Telmisartan was well tolerated by all patients throughout
the study: however, a significant hypotension episodeFigure 2 Strain Rate analysis with TDI in the two arms.(blood pressure values < 95/50 mmHg) was observed only
once in 2 patients (approximately corresponding to t2 and
t3). For this event, the telmisartan dose was reduced from
40 mg to 20 mg/day for 2 subsequent weeks and there-
after the full dose of 40 mg/day was re-established.
As for EPI-related side effects, the only significant adverse
event was a grade 3/4 neutropenia observed at t3 in 6
patients, who needed the administration of Granulocyte
Colony-Stimulating Factor and a postponement of the
subsequent EPI-based cycle.Discussion
The present study confirms the results reported in our
previous work (Dessi, et al. 2011) and moreover adds
important novel findings: i) a reduction in the SR peak
at t2 in both treatment arms with no statistical difference
between the two arms; ii) a persistent reduction in the
SR peak in the placebo arm at t3 and t4 and, more im-
portantly, a reduction of SR peak persisting also at 18-
month FU; iii) a recovery of the SR peak in the
















Figure 3 Serum levels of IL-6 (pg/ml) during the EPI treatment and FU in the telmisartan and placebo arms.
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month FU (data shown for the first time in the present
study); iv) a significant increase of serum levels of IL-6
in the placebo arm from t0 to t2, and a subsequent
decrease to the baseline range up to 18-month FU (the
latter is a new finding), whereas serum levels of IL-6 in
the telmisartan arm remained unchanged from t0 to
18-month FU; v) blood levels of ROS show a super
imposable pattern to that of IL-6; and vi) changes in the
SR peak, an echocardiographic equivalent of early myo-
cardial systolic dysfunction revealed by TDI, correlate
with changes in the levels of IL-6 and ROS, which are
indicative of the body inflammatory and oxidative stress
status, in both arms. Based on the pre-planned early
stopping rules (see Statistical Analysis section) the study








baseline t1 t2 t3 t4
*
*
Figure 4 Blood levels of ROS (FORT U) during the EPI treatment and Fthe study, due to ethical reasons, for the evident super-
iority of the telmisartan arm.
The findings of the present study confirms that AT1R
blockade by telmisartan, administered 1 week before and
throughout the duration of EPI treatment, is able to ini-
tially (t2) reduce and later (t3 and t4) reverse EPI-induced
cardiac abnormalities. This effect is long-lasting and
persisted at 18 month FU. Moreover, telmisartan co-
administration also prevents increases in IL-6 and ROS
levels after EPI administration.
In previous reports, we found that a measurable decline
in the SR peak, currently regarded as the earliest sign of
subclinical CTX, may be detected in EPI-treated patients
long before the clinical evidence of heart failure (Mercuro,
et al. 2007). The subtle systolic impairment appeared
after 200 mg/m2 EPI, a dose which was, until recently,3 mo-FU 6 mo-FU 12 mo-FU 18 mo-FU
telmisartan
placebo
U in the telmisartan and placebo arms.
Table 5 Inflammation and oxidative stress markers in both arms
Parameters t0 (n = 49) t2 (n = 49) t3 (n = 49) t4 (n = 49) 12-Month FU (n = 44) 18-Month FU (n = 44) P - value (ANOVA test)
TNFα
PLA 30.1 ± 9.0 47.1 ± 4.6 30.0 ± 14.4 25.8 ± 8.6 30.0 ± 14.4 8.3 ± 8.4 0.32
TEL 23.5 ± 5.5 22.3 ± 10.6 35.1 ± 8.6 25.9 ± 4.2 35.1 ± 8.6 12.1 ± 2.9 0.56
GPx
PLA 7.386 ± 3.041 6.898 ± 1.552 9.427 ± 3.078 10.232 ± 1.875 9.427 ± 3.078 11669 ± 3336 0.56
TEL 7.415 ± 2.182 6.381 ± 2.137 7.263 ± 2.998 7.479 ± 1.769 7.263 ± 2.998 8507 ± 2316 0.88
SOD
PLA 130.0 ± 9.2 138.0 ± 2.1 193.0 ± 41.0 148.0 ± 38.0 135.0 ± 26.0 134 ± 31 0.32
TEL 126.1 ± 41.6 150.0 ± 37.0 140.0 ± 40.0 145.0 ± 74.0 150.0 ± 37.0 169.5 ± 70 0.95
TNF, tumor necrosis factor; GPx, glutathione peroxidase; SOD, superoxide dismutase.
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et al. 2002). Moreover, a progressive EPI-induced myocar-
dial dysfunction, which was present even at the 18-month
FU in a population of patients not treated with
cardioprotective drugs (Mantovani, et al. 2008), was not
noted in the present study in the telmisartan arm. As
reported above, telmisartan was shown to reverse the early
myocardial dysfunction observed at 200 mg/m2 EPI and,
importantly, its beneficial cardioprotective effect persisted
up to the 18-month FU, i.e., 18 months after discontinu-
ation of EPI chemotherapy and 12 months after the end of
telmisartan coverage.
A large body of evidence has confirmed the role of the
AT1Rs in mediating the damage caused by myocardial
ischemia/reperfusion, resulting from acute ANT-induced
CTX (Jalowy, et al. 1998, Ferreira, et al. 2008). Accord-
ingly, ANTs were found to induce myofibrillar loss,
increase the number of apoptotic cells and significantly
impair cardiac function in control mice, but not in AT1R-
knockout mice or in animals treated with an AT1R antag-
onist (Toko, et al. 2002). This evidence suggests that an
ARB, such as telmisartan, may be able to prevent, at
dosages over 200 mg/m2 EPI, ANT-induced CTX.
In a recent study, a protective effect of telmisartan
against acute ANT-induced CTX was shown in rats:
pre-treatment with the ARB telmisartan elicited a
normalization of significant biochemical parameters and
reduced cardiac tissue damage (Iqbal, et al. 2008).
Therefore, the present study supports the previously
reported role of the RAS in the pathophysiology of
chemotherapy-induced CTX; in particular, it also demon-
strates for the first time, in a clinical trial, the anti-
inflammatory and antioxidant properties of telmisartan,
previously observed only in pre-clinical models
(Cianchetti, et al. 2008). Moreover, the beneficial effect
shown by telmisartan may be explained by its multiple
therapeutic characteristics. Indeed, telmisartan is a unique
ARB with selective PPAR-γ-modulating activity which
affects nitric oxide bioavailability thus leading to its anti-inflammatory, antioxidant and anti-proliferative effects on
vascular wall cells (Yamagishi and Takeuchi 2005).
Telmisartan was also shown to be able to increase the
number of regenerative endothelial progenitor cells and
improve endothelial function independently of its blood
pressure lowering action (Pelliccia, et al. 2010). Addition-
ally, it has also been shown to play a role in lipid and glu-
cose metabolism (Tuck 2005).
Cytokines, sensitive markers of tissue damage, are re-
sponsible for a negative inotropic effect in the failing hu-
man heart (Escobar, et al. 2004, Iqbal, et al. 2008) and in
the pathophysiology of dilated cardiomyopathy (Tuck
2005). The increase in proinflammatory cytokines (IL-6)
and oxidative stress markers (Thompson, et al. 2010) after
EPI administration confirms that systemic inflammation/
oxidative stress plays a central role in the cardiac damage
induced by EPI. Indeed, significant correlations between
cytokines/ROS levels and SR decline, observed in our pre-
vious study (Mantovani, et al. 2008) and confirmed in the
placebo arm of the present trial, suggest that an increase
in inflammatory/ROS markers may be analogous to early
myocardial cell dysfunction shown by TDI.
A pathogenetic hypothesis based on oxidative stress
has gained the widest acceptance in the study of acute
EPI-induced CTX. Its molecular basis is attributable to
the one-electron redox cycling of the quinone moiety,
which generates ROS in excess of limited cardiomyocyte
antioxidant defenses (Minotti, et al. 2004). This cellular
pathway results in severe oxidative stress and disruption
of the mitochondrial energetic machinery, ultimately
leading to cardiomyocyte apoptosis or necrosis (Conklin
2005). Indeed, a relationship was found between cyto-
kine release and ROS increase in patients with dilated
cardiomyopathy (Kaur, et al. 2006).
The observation that telmisartan is able to prevent, at
dosages over 200 mg/m2 EPI, such a number of poten-
tially harmful effects induced by EPI, to which, however,
its antineoplastic therapeutic efficacy is attributable, sug-
gests that its administration may also compromise or
Dessì et al. SpringerPlus 2013, 2:198 Page 9 of 10
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ever, this hypothesis is not supported by any data in the
literature.
Regarding the use of telmisartan as a cardioprotective
drug in our present trial, it is to be noted that recently
(July 2010), and long after the beginning of our study (end
of 2008) and concomitantly with the publication of the
first results (September 2010), a meta-analysis was pub-
lished by Sipahi et al. (Sipahi, et al. 2010). The authors
concluded that when the analysis was limited to
telmisartan, the excess in new cancer (lung cancer) occur-
rence was of borderline significance (p = 0.05) and that no
statistically significant difference in cancer deaths was
observed. Furthermore, the telmisartan dose used in the
trials which were reviewed in the meta-analysis was
80 mg/day, i.e., double the dose used in our trial. For these
reasons we believe that the findings of Sipahi et al. have
no bearing on our study.
The potential shortcoming of the present study is the
limited number of patients included: therefore, a con-
firmatory phase III randomized multicenter and possibly
multinational trial is warranted.
In conclusion, the present study strengthens the find-
ings of our earlier research (Cadeddu, et al. 2010) which
aimed to assess the cardioprotective effect of telmisartan
only during the period of EPI administration. It high-
lights that the protection obtained with the AT1R block-
ade has a long-lasting effect, probably by ensuring a
permanent (at least up to 18-month FU) defense against
chronic or late-onset types of ANT-induced CTX. This
finding is extremely important, since ANT-induced CTX
persists for years with no clinical symptoms, whereas
upon the development of overt heart failure, the progno-
sis becomes extremely poor, possibly even worse than
that of ischemic or idiopathic dilated cardiomyopathy
(Cardinale, et al. 2008, Cardinale, et al. 2013, Colombo
and Cardinale 2013).
The future potential development of the present study
is thus to continuously monitor these two group of pa-
tients to evaluate whether the global cardiac function in
the long term, at least for 3 years, is comparable between
the two groups or whether the group protected with
telmisartan has a better global cardiac function and thus
a better clinical outcome. For this purpose the study is
still in progress.
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